Chase C. Leavitt is Secretary at Oncternal Therapeutics, Inc. (ONCT). They have made 6 open-market trades across 3 companies since 2019, most recently 2026-09-11.
CIK 0001777467
6 open-market purchases totalling $109K since 2019, never a sale. Across 5 scored buys the stock is down 7.2% at ninety days, and 11.0 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ONCT | 84,758 | $45K |
| MOBI | 5,000 | $40K |
| LCTX | 5,000 | $5K |
| Total | $90K |
Shares reported on the most recent Form 4, priced at the 2026-09-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 33% | 40% |
| Avg Move | -5.4% | -8.9% | -7.2% |
| Alpha | -5.5% | -9.7% | -11.0% |
| Scored | 6 | 6 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MOBI | BUY | 2026-09-11 | 2026-09-15 | $10.30 | $21K | -16.2% | -23.2% | — |
| MOBI | BUY | 2026-05-11 | 2026-05-11 | $15.00 | $45K | +3.6% | +4.7% | +5.1% |
| ONCT | BUY | 2023-04-12 | 2023-04-14 | $0.29 | $7K | -11.7% | -11.9% | +43.3% |
| ONCT | BUY | 2022-01-27 | 2022-01-31 | $1.72 | $23K | +5.6% | -7.7% | -46.2% |
| ONCT | BUY | 2021-06-11 | 2021-06-15 | $5.45 | $8K | -3.6% | -22.1% | -20.4% |
| LCTX | BUY | 2019-08-13 | 2019-08-15 | $1.02 | $5K | -10.1% | +6.6% | -17.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.